Mia Gatti
Physician Assistants (Physician Assistant)
At a glance
- In the NPI registry since
- 2014
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2014Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Physician Assistant primary
CA license 51400
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 288 | 60 |
| Established patient office or other outpatient visit, 20-29 minutes | 136 | 119 |
| Destruction of precancer skin growth, 1 growth | 80 | 75 |
| Biopsy of related skin growth, first growth | 34 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $290 in total to this clinician.
| AbbVie Inc. | $151 |
|---|---|
| Revance Therapeutics, Inc. | $48.61 |
| E.r. Squibb & Sons, L.l.c. | $40.56 |
| Amgen Inc. | $27.07 |
| Pfizer Inc. | $23.22 |
| Food and Beverage | $290 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $69,728 in research payments for these studies, mostly to the institutions running them.
- Open Label, Long-term Study Evaluating Safety and Efficacy of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis
Sanofi US Services Inc. · Active, not recruiting · NCT05769777 - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
Sanofi US Services Inc. · Active, not recruiting · NCT06241118
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.